Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: A novel molecular mechanism

Journal of Thoracic Oncology

Volumn 3, Issue 8, 2008, Pages 943-944

  Namazi, Hamid ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYL BETA CYCLODEXTRIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; TUMOR MARKER;

ADVANCED CANCER; BONE METABOLISM; BONE METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CELL ACTIVITY; CELL MATURATION; CELL MEMBRANE; DRUG MECHANISM; HUMAN; LETTER; LUNG CANCER; MALE; MESENCHYME; MOLECULAR DYNAMICS; OSTEOCLAST; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; BONE TUMOR; LUNG TUMOR; METABOLISM; MORTALITY; NOTE; SURVIVAL RATE;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; OSTEOCLASTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 58149128159     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318180721d     Document Type: Letter

References (10)

1. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236.
2. Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is responsible for osteolysis in a C4 -2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 2007;7:148.
3. Affara NI, Coussens LM. IKKalpha at the crossroads of inflammation and metastasis. Cell 2007;129:25-26.
4. Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 2006;23:9-18.
5. Whitfield JF. How to grow bone to treat osteoporosis and mend fractures. Curr Rheumatol Rep 2003;5:45-56.
6. Edwards CJ, Spector TD. Statins as modulators of bone formation. Arthritis Res 2002;4: 151-153.
7. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006;103:7829-7834.
8. Coxan FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-312.
9. Martini G, Gennari L, Merlotti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007;40:457-463.
10. Dobring H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006;17:693-703.